Van ECK Associates Corp Sells 78,784 Shares of Core Laboratories Inc. $CLB

Posted by George Bondi on Sep 3rd, 2026

Van ECK Associates Corp trimmed its holdings in Core Laboratories Inc. (NYSE:CLB – Free Report) by 16.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 393,682 shares of the oil and gas company’s stock after selling 78,784 shares during the period. Van ECK Associates Corp’s holdings in Core Laboratories were worth $4,586,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in CLB. Summit Securities Group LLC purchased a new position in Core Laboratories in the 1st quarter worth approximately $31,000. Aster Capital Management DIFC Ltd purchased a new stake in Core Laboratories during the 4th quarter valued at approximately $34,000. CWM LLC raised its position in shares of Core Laboratories by 36.1% during the fourth quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock valued at $40,000 after buying an additional 668 shares during the last quarter. Quarry LP raised its position in shares of Core Laboratories by 118.1% during the third quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock valued at $36,000 after buying an additional 1,599 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its holdings in shares of Core Laboratories by 124.7% in the fourth quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company’s stock worth $51,000 after buying an additional 1,763 shares in the last quarter. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Insider Transactions at Core Laboratories

In other news, CEO Lawrence Bruno acquired 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was bought at an average cost of $10.78 per share, with a total value of $53,900.00. Following the completion of the purchase, the chief executive officer directly owned 262,438 shares of the company’s stock, valued at $2,829,081.64. This represents a 1.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.26% of the stock is currently owned by corporate insiders.

Core Laboratories Stock Up 0.7%

Shares of NYSE:CLB opened at $12.48 on Thursday. The company has a market cap of $572.49 million, a price-to-earnings ratio of 22.28, a PEG ratio of 2.45 and a beta of 1.08. Core Laboratories Inc. has a 12 month low of $9.79 and a 12 month high of $20.36. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $11.61 and a 200 day moving average price of $14.05.

Core Laboratories (NYSE:CLB – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $124.61 million during the quarter, compared to analyst estimates of $126.26 million. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The company’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same period last year, the company earned $0.19 EPS. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. As a group, equities research analysts predict that Core Laboratories Inc. will post 0.56 earnings per share for the current year.

Core Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Monday, August 10th were given a $0.01 dividend. The ex-dividend date was Monday, August 10th. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. Core Laboratories’s dividend payout ratio (DPR) is currently 7.14%.

Wall Street Analyst Weigh In

CLB has been the subject of a number of research reports. Weiss Ratings upgraded shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Johnson Rice upgraded shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research note on Thursday, August 13th. Finally, Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.00.

Get Our Latest Stock Report on CLB

Core Laboratories Company Profile

(Free Report)

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.